CBI

Leading life science success

CBI is Israel’s largest life sciences holding company

about cbi

Clal Biotechnology Industries (TASE: CBI) is Israel’s leading life sciences investment company. CBI supports life sciences by identifying and powering science backed ventures and proactively guiding them to transform the healthcare industry.

portfolio

The CBI portfolio is comprised of biotechnology and medical device companies developing breakthrough solutions for serious unmet medical needs, while offering substantial value and investment potential.

+

MediWound

MediWound (Nasdaq: MDWD) is a specialty biotechnology company focused on the fields of severe burn and chronic wound management.
+

Gamida Cell

Gamida Cell is a cell and immune therapy visionary. Lead product, NiCord® is currently in phase III clinical trial in hematological malignancies.
+

Anchiano (formerly Biocancell)

Anchiano Therapeutics (TASE: ANCN) is a clinical stage biopharmaceutical company dedicated to developing new therapies for non-muscle-invasive bladder cancer.
+

Vedantra

Vedantra develops platform technologies to deliver agents directly to the antigen-presenting cells of the lymph nodes with potential application in both cancer and infectious disease.
+

Neon Therapeutics

Neon Therapeutics is a clinical stage, immuno-oncology company focused on developing novel therapeutics leveraging neoantigen biology to treat cancer.
+

Cadent Therapeutics

Cadent Therapeutics is developing novel drugs for neurological and psychiatric disorders.
+

Exithera

eXIthera Pharmaceuticals is a clinical stage biotech company focused on discovering and developing Factor XIa inhibitors for the prevention of stroke and thrombosis.
+

Biokine

Biokine Therapeutics is company focused on developing novel therapeutics to treat cancer. It's lead product, BL-8040, is licensed to BiolineRx and is entering phase III clinical trial.
+

CureTech

CureTech is a biotechnology company developing novel immune modulating products. Its lead product, pidilizumab (CT-011), was evaluated in multiple cancer indications.

See complete portfolio

Press Releases

2019

20

Mar

MediWound Announces Executive Leadership Changes
21

Feb

Gamida Cell Presents Data from Ongoing Phase 1 Study of NAM-NK and Initial Data from Phase 1/2 Study of NiCord® in Severe Aplastic Anemia
12

Feb

Anchiano Therapeutics Announces Pricing of a $30.5 Million Initial Public Offering
05

Feb

BioLineRx Receives Orphan Drug Designation from the FDA for Lead Candidate BL-8040 for the Treatment of Pancreatic Cancer
27

Jan

Gamida Cell Announces Data from NAM-NK and NiCord® Programs to Be Presented at the 2019 TCT Meeting
22

Jan

MediWound Announces Positive Top-Line Results from Its Pivotal Phase 3 Study of NexoBrid® for Eschar Removal in Severe Thermal Burns

Read all Press Releases